ABSTRACT
AIMS: The number of patients with heart failure (HF) and implantable cardiac electronic devices has been growing steadily. Remote monitoring care (RC) of cardiac implantable electronic devices can facilitate patient-healthcare clinical interactions and prompt preventive activities to improve HF outcomes. However, studies that have investigated the efficacy of remote monitoring have shown mixed findings, with better results for the system including daily verification of transmission. The purpose of the RESULT study was to analyse the impact of remote monitoring on clinical outcomes in HF patients with implantable cardioverter-defibrillator [ICD/cardiac resynchronization therapy-defibrillator (CRT-D)] in real-life conditions. METHODS AND RESULTS: The RESULT is a prospective, single-centre, randomized trial. Patients with HF and de novo ICD or CRT-D implantation were randomized to undergo RC vs. in-office follow-ups (SC, standard care). The primary endpoint was a composite of all-cause death and hospitalization due to cardiovascular reasons within 12 months after randomization. We randomly assigned 600 eligible patients (299 in RC vs. 301 in SC). Baseline clinical and echocardiographic characteristics were well-balanced and similar in both arms. The incidence of the primary endpoint differed significantly between RC and SC and involved 39.5% and 48.5% of patients, respectively, (P = 0.048) within the 12-month follow-up. The rate of all-cause mortality was similar between the studied groups (6% vs. 6%, P = 0.9), whereas hospitalization rate due to cardiovascular reasons was higher in SC (37.1% vs. 45.5%, P = 0.045). CONCLUSION: Remote monitoring of HF patients with implanted ICD or CRT-D significantly reduced the primary endpoint rate, mostly as a result of a lower hospitalization rate in the RC arm (ClinicalTrials.gov Identifier: NCT02409225).
Subject(s)
Cardiac Resynchronization Therapy , Defibrillators, Implantable , Heart Failure , Heart Failure/diagnosis , Heart Failure/therapy , Hospitalization , Humans , Prospective Studies , Treatment OutcomeABSTRACT
OBJECTIVES: We sought to determine the 1-year clinical follow-up in patients treated with the thin strut (71 µm) bioabsorbable polymer-coated sirolimus-eluting stent (BP-SES) vs durable coating everolimus eluting stent (DP-EES) in daily clinical routine. BACKGROUND: Presence of durable polymers may be associated with late/very late stent thrombosis occurrence and the need for prolonged dual antiplatelet therapy. Bioabsorbable polymers may facilitate stent healing, thus enhancing clinical safety. METHODS: Interventional Cardiology Network Registry is a prospective, multicenter, observational registry of 21,400 consecutive patients treated with PCI since 2010. We analyzed 4,670 patients treated with either a BP-SES (ALEX, Balton, Poland) or DP-EES (XIENCE, Abbott, USA) with available 1-year clinical follow-up using propensity-score matching. Outcomes included target vessel revascularization (TVR) as efficacy outcome and all cause death, myocardial infarction (MI), and definite/probable stent thrombosis as safety outcomes. RESULTS: After propensity score matching, 1,649 patients treated with BP-SES and 1,649 patients treated with DP-EES were selected. Procedural and clinical characteristics were similar between both groups. There was no significant difference between tested groups in in-hospital mortality. One-year follow-up demonstrated comparable efficacy outcome, TVR (BP-SES 5.9% vs DP-EES 4.6% P = 0.45), as well as comparable safety outcomes, all cause death, MI and definite/probable stent thrombosis. CONCLUSIONS: In this multicenter registry, the BP-SES thin strut biodegradable polymer-coated sirolimus-eluting stent demonstrated comparable clinical outcomes at 1-year after implantation to the DP-EES. These data support the relative safety and efficacy of DP-SES in a broad range of patients undergoing percutaneous coronary intervention.
Subject(s)
Absorbable Implants , Angioplasty, Balloon, Coronary/instrumentation , Cardiovascular Agents/administration & dosage , Coronary Artery Disease/therapy , Drug-Eluting Stents , Polymers , Sirolimus/administration & dosage , Aged , Angioplasty, Balloon, Coronary/adverse effects , Angioplasty, Balloon, Coronary/mortality , Cardiovascular Agents/adverse effects , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Everolimus/administration & dosage , Female , Humans , Male , Middle Aged , Poland , Propensity Score , Prosthesis Design , Registries , Retrospective Studies , Risk Assessment , Risk Factors , Sirolimus/adverse effects , Time Factors , Treatment OutcomeABSTRACT
Aim: To investigate the characteristics long-term prognostic implications (up to â¼2.2 years) of atrial fibrillation (AF) compared to sinus rhythm (SR), between acute and chronic heart failure (HF) with reduced (HFrEF < 40%), mid-range (HFmrEF 40-49%), and preserved (HFpEF ≥ 50%) ejection fraction (EF). Methods and results: Data from the observational, prospective, HF long-term registry of the European Society of Cardiology were analysed. A total of 14 964 HF patients (age 66 ± 13 years, 67% male; 53% HFrEF, 21% HFmrEF, 26% HFpEF) were enrolled. The prevalence of AF was 27% in HFrEF, 29% in HFmrEF, and 39% in HFpEF. Atrial fibrillation was associated with older age, lower functional capacity, and heightened physical signs of HF. Crude rates of mortality and HF hospitalization were higher in patients with AF compared to SR, in each EF subtype. After multivariable adjustment, the hazard ratio of AF for HF hospitalizations was: 1.036 (95% CI 0.888-1.208, P = 0.652) in HFrEF, 1.430 (95% CI 1.087-1.882, P = 0.011) in HFmrEF, and 1.487 (95% CI 1.195-1.851, P < 0.001) in HFpEF; and for combined all-cause death or HF hospitalizations: 0.957 (95% CI 0.843-1.087, P = 0.502), 1.302 (95% CI 1.055-1.608, P = 0.014), and 1.365 (95% CI 1.152-1.619, P < 0.001), respectively. In patients with HFrEF, AF was not associated with worse outcomes in those presenting with either an acute or a chronic presentation of HF. Conclusions: The prevalence of AF increases with increasing EF but its association with worse cardiovascular outcomes, remained significant in patients with HFpEF and HFmrEF, but not in those with HFrEF.
Subject(s)
Atrial Fibrillation/complications , Heart Failure/mortality , Societies, Medical/organization & administration , Stroke Volume/physiology , Aged , Atrial Fibrillation/epidemiology , Atrial Fibrillation/physiopathology , Cardiology/organization & administration , Cause of Death/trends , Europe/epidemiology , Female , Heart Failure/epidemiology , Heart Failure/physiopathology , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Prevalence , Prognosis , Prospective StudiesABSTRACT
BACKGROUND: Randomized controlled trials demonstrate that remote monitoring (RM) of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds) may improve quality of care and prognosis in heart failure (HF) patients. However, the impact of RM on long-term mortality in a real-world cohort is still not well examined. METHODS AND RESULTS: This study was designed as a matched cohort study based on the COMMIT-HF trial--a single-center, ongoing prospective observational registry (NCT02536443). Complete patient demographics, medical history, in-hospital results, hospitalizations, and mortality data were collected based on institutional registries and healthcare providers' records. Patients were divided into 2 groups based on RM presence and matched by means of propensity scores according to clinical characteristics. The primary endpoint of this study was the long-term all-cause mortality. Out of 1,429 consecutive patients, 822 patients with a first implantation of an ICD/CRT-D were included in the analysis. The final matched study population contained 574 patients in RM and in a control group. Although demographic and echocardiographic parameters as well as pharmacological treatments were similar in both groups, a significantly lower 1-year mortality was detected in the RM group (2.1% vs. 11.5%, P < 0.0001). This was also maintained during a 3-year follow-up (4.9% vs. 22.3%, P < 0.0001). Multivariate analysis showed that RM was associated with an improved prognosis (hazard ratio 0.187, 95% confidence interval 0.075-0.467, P = 0.0003). CONCLUSION: RM of HF patients with ICDs/CRT-Ds significantly reduced long-term mortality in a real-world clinical condition.
Subject(s)
Heart Failure/diagnosis , Telemedicine/methods , Telemetry , Aged , Cardiac Resynchronization Therapy , Cardiac Resynchronization Therapy Devices , Chi-Square Distribution , Defibrillators, Implantable , Electric Countershock/instrumentation , Female , Heart Failure/mortality , Heart Failure/physiopathology , Heart Failure/therapy , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Prognosis , Propensity Score , Proportional Hazards Models , Prospective Studies , Prosthesis Design , Registries , Risk Factors , Time FactorsABSTRACT
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Subject(s)
Defibrillators, Implantable/statistics & numerical data , Heart Failure/therapy , Hospitalization/statistics & numerical data , Pacemaker, Artificial/statistics & numerical data , Research Design , Telemedicine/methods , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective Studies , Young AdultABSTRACT
Aim: To assess risk factors and prognosis in patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock (CS) in Poland. Methods: Data from The Polish Registry of Acute Coronary Syndromes (PL-ACS) were analysed in 2008-2012. A total of 57400 consecutive STEMI patients included. The results of treatment and prognosis of patients with and without CS were compared. An additional analysis of the prognosis of men and women with CS was performed. Results: There were 34.2% of women and 65.8% of men. CS was diagnosed in 3589 (6.3%) patients (females 7.3% vs. males 5.7%, p<0.003). In multivariate analysis CS was the strongest factor affecting both inhospital (OR 2.51; 95%CI 2.25-2.80; p<0.0001) and 12-month (OR 2.09; 95%CI 1.96-2.24; p<0.0001) mortality. The worst prognosis was associated with pulmonary edema, advanced age, left or right bundle branch block, atrial fibrillation, and anterior MI. An early invasive strategy up to six hours from the symptom onset were the only factors reducing in-hospital and 12-month mortality. Despite of high female ratio in the group with CS and higher mortality in the female group, the female sex did not influence the in-hospital prognosis. Conclusion: In spite of enormous progress in the treatment of STEMI cardiogenic shock remains an important complication affecting the in-hospital and long-term prognosis. A symptom onset-to-treatment time is the key element in the management of patients with CS. Proper diagnosis and management including wide interventional strategy implementation increase the survival chance. An intensive study on novel treatment modalities and on effective identification methods of patients at risk and are warranted.
Subject(s)
Registries , ST Elevation Myocardial Infarction/etiology , Shock, Cardiogenic/etiology , Age Factors , Aged , Aged, 80 and over , Atrial Fibrillation , Female , Humans , Male , Middle Aged , Poland , Prognosis , Pulmonary Edema , Risk Factors , ST Elevation Myocardial Infarction/complications , ST Elevation Myocardial Infarction/ethnology , ST Elevation Myocardial Infarction/therapy , Shock, Cardiogenic/complications , Shock, Cardiogenic/ethnology , Shock, Cardiogenic/therapyABSTRACT
BACKGROUND: The no-reflow (NR) phenomenon exists despite percutaneous coronary intervention (PCI), and is especially prevalent in diabetics. The causes(s) of NR are not fully elucidated, but may be associated with impaired residual platelet and inflammatory reactivity during dual-antiplatelet therapy. OBJECTIVE: To assess the relationship between dual-antiplatelet therapy, NR and conventional biomarkers suggestive of platelet and inflammatory response in diabetics following ST-segment elevation myocardial infarction (STEMI) treated with PCI. METHODS: Sixty diabetics with (n = 27) and without NR (n = 33) were prospectively enrolled. All patients were treated with clopidogrel and aspirin. Platelet and inflammatory biomarkers were assessed serially in the peripheral blood and right atrium before and after PCI and then at 24 h, 7 days and 30 days. RESULTS: Arachidonic acid (AA)-induced platelet aggregation and the serum thromboxane B2 level before and after PCI (in the peripheral and right atrium blood) were significantly higher in the NR patients than in those with no NR. AA-induced aggregation >100 (AUC*min) before PCI predicted NR in diabetic patients with 96.2% sensitivity and 38.5% specificity (AUC 0.66; 95% CI 0.52-0.71; p = 0.029). There were no other correlations between NR and platelet reactivity (collagen, adenosine diphosphate, thrombin receptor agonist peptide-induced aggregation, vasodilator-stimulated phosphoprotein platelet reactivity index, soluble P-selectin, soluble CD40 ligand, platelet-derived growth factor AB and the level of platelet-monocyte aggregates) or between NR and inflammatory indices (i.e. high-sensitivity C-reactive protein, interleukin 6 and interleukin 10). CONCLUSION: An inadequate response to aspirin, but not to clopidogrel, may be associated with the occurrence of the NR phenomenon in diabetics with STEMI who have been treated with primary PCI.
Subject(s)
Diabetes Complications/etiology , Myocardial Infarction/complications , No-Reflow Phenomenon/etiology , Platelet Aggregation Inhibitors/therapeutic use , Platelet Aggregation , Aged , Aspirin/therapeutic use , Biomarkers/blood , Clopidogrel , Diabetes Complications/blood , Drug Resistance , Female , Humans , Inflammation/blood , Male , Middle Aged , Myocardial Infarction/therapy , No-Reflow Phenomenon/blood , Percutaneous Coronary Intervention , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic useABSTRACT
AIMS: The prognosis in men and women with myocardial infarction due to left main coronary artery disease (LM) in relation to the presence of isolated LM disease or accompanying one-, two- or multivessel disease. MATERIALS AND METHODS: A total of 643 consecutive patients (184 females, 459 males) with acute myocardial infarction due to LM stenosis or occlusion were enrolled. Data on clinical presentation, management and in-hospital mortality derived from the Polish Registry of Acute Coronary Syndromes PL-ACS, data on 12-month mortality derived from the Civil Registry. Patients with isolated LM disease were compared with patients in whom significant stenosis in artery another than LM was present. In-hospital, 30-day, 6- and 12-month mortality in both genders were analyzed. RESULTS: The disease severity was similar in men and women. No difference in mortality between all subgroups was observed. A non-significant trend towards higher mortality in patients with multivessel disease accompanying to LM disease when compared to patients with isolated LM disease (34.2% vs. 25.2%; p log rank = 0.06). CONCLUSIONS: There was no difference in in-hospital and long-term mortality between patients with isolated LM disease vs. patients with accompanying multivessel disease. No difference in mortality between genders was noticed. A longer follow-up is needed to confirm the significance of higher mortality in patients with multivessel disease.
Subject(s)
Coronary Artery Disease/epidemiology , Myocardial Infarction/epidemiology , Comorbidity , Coronary Artery Disease/classification , Female , Hospital Mortality , Humans , Male , Poland/epidemiology , Prognosis , Survival RateABSTRACT
BACKGROUND: Diabetes is a significant risk factor in patients with non ST-segment elevation myocardial infarction (NSTEMI). Sex-related differences in clinical course of NSTEMI have not been extensively studied. MATERIAL AND METHODS: During one year all consecutive patients presenting with NSTEMI and diabetes were enrolled. A total of 298 (158 women and 140 men) were analyzed. Clinical presentation, applied treatment and prognosis were compared between women and men. RESULTS: Women tended to be older. More men smoked cigarettes. Pharmacological approach was similar in both groups. Men underwent revascularization more often. Despite those differences both short- and long-term mortality were comparable. CONCLUSION: Despite the common knowledge on negative influence of diabetes and female sex in NSTEMI patients, in multivariate analysis only age and three or four Killip class on admission were significant.
Subject(s)
Diabetes Mellitus/epidemiology , Myocardial Infarction/epidemiology , Smoking/epidemiology , Age Distribution , Age Factors , Aged , Aged, 80 and over , Comorbidity , Female , Humans , Male , Multivariate Analysis , Myocardial Infarction/therapy , Myocardial Revascularization/statistics & numerical data , Poland/epidemiology , Prognosis , Risk Factors , Sex Distribution , Sex Factors , Survival RateABSTRACT
The distribution of atherosclerotic plaque burden in the human coronary arteries is not uniform. Plaques are located mostly in the left anterior descending artery (LAD), then in the right coronary artery (RCA), circumflex branch (LCx) and the left main coronary artery (LM) in a decreasing order of frequency. In the LAD and LCx, plaques tend to cluster within the proximal segment, while in the RCA their distribution is more uniform. Several factors have been involved in this phenomenon, particularly flow patterns in the left and right coronary artery. Nevertheless, it does not explain the difference in lesion frequency between the LAD and the LCx as these are both parts of the left coronary artery. Branching points are considered to be the risk points of atherosclerosis. In the LCx, the number of side branches is lower than in the LAD or RCA and there are no septal perforators with intramuscular courses like in the proximal third of the LAD and the posterior descending artery (PDA). We hypothesized that septal branches generate disturbed flow in the LAD and PDA in a similar fashion to the myocardial bridge (myocardial bridging effect). This coronary architecture determines the non-uniform plaque distribution in coronary arteries and LAD predisposition to plaque formation.
ABSTRACT
OBJECTIVES: Increased plasma thrombogenesis and blood platelet reactivity are associated with a worse outcome in patients with the acute coronary syndrome (ACS). The aim of this study was to test the clinical utility of combining a thrombin generation test and platelet aggregation in predicting future ischemic events after ACS. METHODS: The study included patients hospitalized due to ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention with stent implantation. Blood for platelet aggregation and thrombin generation was collected at hospital discharge. We performed whole-blood platelet aggregation with arachidonic acid (AA), collagen, adenosine diphosphate and thrombin receptor-activating peptide (TRAP) as agonists and the thrombin generation test using a fluorescence method. Patients were followed for up to 6 months. The combined end point of the study consisted of death, stroke, myocardial infarction or repeated target vessel revascularization. RESULTS: The study enrolled 161 patients. The end point occurred in 30 patients (18.6%). Thrombin generation showed a significantly prolonged lag time, time to thrombogram peak and start of the tail of the thrombogram in diabetic patients who reached the study end point but not in nondiabetics. End point occurrence was not connected with platelet reactivity at hospital discharge in the whole group. In the diabetic subgroup, increased platelet aggregation induced with AA and TRAP at hospital discharge was connected with a more frequent occurrence of the study end point. CONCLUSIONS: In diabetic patients after STEMI, thrombin generation measures as well as TRAP- and AA-induced platelet aggregation at hospital discharge are associated with an ensuing ischemic event during the 6-month follow-up.
Subject(s)
Acute Coronary Syndrome/blood , Diabetes Complications/blood , Myocardial Infarction/blood , Platelet Aggregation , Thrombin/metabolism , Acute Coronary Syndrome/complications , Adult , Aged , Case-Control Studies , Diabetes Complications/etiology , Female , Healthy Volunteers , Humans , Male , Middle Aged , Myocardial Infarction/etiology , Myocardial Infarction/surgery , Percutaneous Coronary InterventionABSTRACT
In the general population, the lowest mortality risk is considered to be for the body mass index (BMI) range of 20-24.9 kg/m(2). In chronic diseases (chronic kidney disease, chronic heart failure or chronic obstructive pulmonary disease) the best survival is observed in overweight or obese patients. Recently above-mentioned phenomenon, called obesity paradox, has been described in patients with coronary artery disease. Our aim was to analyze the relationship between BMI and total mortality in patients after acute coronary syndrome (ACS) in the context of obesity paradox. We searched scientific databases for studies describing relation in body mass index with mortality in patients with ACS. The study selection process was performed according to PRISMA statement. Crude mortality rates, odds ratio or risk ratio for all-cause mortality were extracted from articles and included into meta-analysis. 26 studies and 218,532 patients with ACS were included into meta-analysis. The highest risk of mortality was found in Low BMI patients--RR 1.47 (95 % CI 1.24-1.74). Overweight, obese and severely obese patients had lower mortality compared with those with normal BMI-RR 0.70 (95 % CI 0.64-0.76), RR 0.60, (95 % CI 0.53-0.68) and RR 0.70 (95 % CI 0.58-0.86), respectively. The obesity paradox in patients with ACS has been confirmed. Although it seems to be clear and quite obvious, outcomes should be interpreted with caution. It is remarkable that obese patients had more often diabetes mellitus and/or hypertension, but they were younger and had less bleeding complications, which could have influence on their survival.
Subject(s)
Acute Coronary Syndrome/mortality , Body Mass Index , Obesity/mortality , Acute Coronary Syndrome/complications , Female , Humans , Kaplan-Meier Estimate , Male , Obesity/complicationsABSTRACT
UNLABELLED: The benefit of immediate reperfusion in the treatment of ST-segment elevation myocardial infarction (STEMI) is indisputable. Unfortunately, no reperfusion therapy is applied to nearly 30% of patients without contraindication to such treatment. We aimed to analyze the impact of therapeutic approach on the prognosis after acute phase of STEMI. MATERIAL AND METHODS: The study group consisted of 26035 consecutive STEMI patients (8989 females, 34.4%) hopitalized in 456 sites during one year. Data were available from the Polish Registry of Acute Coronary Syndromes (PL-ACS) launched in Silesian Center for Heart Diseases, Zabrze. RESULTS: Patiens treated with primary percutaneous intervention (pPCI) had the best outcome. All therapeutic strategies resulted in worse prognosis in women when compared to men. Women had greater 12-month mortality in the conservative, fibrinolytic and interventional treatment group: 33.1% vs 23.2%; p < 0.0001; 24.3% vs 16.2%; p < 0.0001 i 11.4% vs 8.2%, p < 0.0001, respectively. Differences in the surgically treated group were insignificant (men: 25%, women: 8%, p = 0.42). CONCLUSIONS: The outcome of conservative, fibrinolytic and interventional treatment was worse in the female group. Primary coronary angioplasty was the most benefical therapeutic strategy.
Subject(s)
Myocardial Infarction/mortality , Myocardial Infarction/therapy , Myocardial Reperfusion , Angioplasty, Balloon, Coronary , Female , Fibrinolytic Agents/therapeutic use , Hospital Mortality , Humans , Length of Stay , Male , Prognosis , Sex Factors , Survival Rate , Treatment OutcomeABSTRACT
AIMS: To assess prognosis in men and women with myocardial infarction (MI) complicated with cardiogenic shock (CS) due to critical stenosis of the unprotected left main coronary artery (ULMCA). METHODS AND RESULTS: A total of 643 (females 28.6%, males 71.4%) consecutive patients with critical ULMCA stenosis and acute MI were included. Data were obtained from the Polish Registry of Acute Coronary Syndromes (PL-ACS). Study end-points were defined as in-hospital death, mortality at 30 days, 6 and 12 months. Of all patients 103 (16.0%) developed CS. Basic characteristics and treatment strategy were similar in both sexes. As many as 95% of patients in CS were treated invasively with PCI. In-hospital mortality among women in CS was lower than among men (43.3% vs. 64.4%, p = 0.049). Mortality at 30 days and 12 months in CS group as well as in patients without CS did not differ significantly between men and women. In multivariate analysis age and CS, but not a female gender, were independent factors of increased mortality whereas only a successful PCI significantly reduced mortality. CONCLUSION: Cardiogenic shock and pulmonary edema were independent factors of mortality. There were no differences in mortality between men and women in subgroups with and without CS. Emergency PCI seems to be a useful and beneficial option in this subset of patients.
Subject(s)
Coronary Artery Disease/epidemiology , Myocardial Infarction/epidemiology , Shock, Cardiogenic/mortality , Aged , Aged, 80 and over , Angioplasty, Balloon, Coronary , Causality , Comorbidity , Coronary Artery Disease/therapy , Female , Humans , Male , Poland , Prognosis , Pulmonary Edema/epidemiology , Sex Distribution , Sex Factors , Survival Rate , Treatment OutcomeABSTRACT
BACKGROUND: Iron deficiency (ID) is an emerging problem in patients with chronic heart failure (HF) and can be a potential therapeutic target. However, not much is known about the prevalence, predictors, and prognosis of ID in patients with chronic HF. METHODS: In an international pooled cohort comprising 1,506 patients with chronic HF, we studied the clinical associates of ID and its prognostic consequences. RESULTS: Iron deficiency (defined as a ferritin level <100 µg/L or ferritin 100-299 µg/L with a transferrin saturation <20%) was present in 753 patients (50%). Anemic patients were more often iron deficient than nonanemic patients (61.2% vs 45.6%, P < .001). Other independent predictors of ID were higher New York Heart Association class, higher N-terminal pro-brain-type natriuretic peptide levels, lower mean corpuscular volume levels, and female sex (all P < .05). During follow-up (median 1.92 years, interquartile range 1.18-3.26 years), 440 patients died (29.2%). Kaplan-Meier survival analysis revealed ID as a strong predictor for mortality (log rank χ(2) 10.2, P = .001). In multivariable hazard models, ID (but not anemia) remained a strong and independent predictor of mortality (hazard ratio 1.42, 95% confidence interval 1.14-1.77, P = .002). Finally, the presence of ID significantly enhanced risk classification and integrated discrimination improvement when added to a prediction model with established risk factors. CONCLUSIONS: Iron deficiency is common in patients with chronic HF, relates to disease severity, and is a strong and independent predictor of outcome. In this study, ID appears to have greater predictive power than anemia.
Subject(s)
Anemia, Iron-Deficiency/epidemiology , Heart Failure/epidemiology , Iron Deficiencies , Aged , Chronic Disease , Female , Heart Failure/mortality , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Risk AssessmentABSTRACT
BACKGROUND: Data regarding the association between red cell distribution width (RDW) values and mortality in patients with stable coronary artery disease are scarce. We aimed to investigate the link between mortality and RDW in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). METHODS: We analyzed 2550 consecutive patients with stable coronary artery disease who underwent PCI between 2007 and 2011 at our institution. The patients were divided into four groups according to RDW quartiles. The association between the RDW values and the outcomes was assessed using Cox proportional regression analysis after adjusting for clinical, echocardiographic, hemodynamic and laboratory data in the whole population and in subgroups stratified by gender, presence of diabetes, anemia or heart failure. RESULTS: In the entire population, there was a stepwise relationship between RDW intervals and comorbidities. Patients with the highest RDW values were older and more often burdened with diabetes, heart failure and chronic kidney disease. There was an almost 4-fold increase in mortality during an average of 2.5 years of follow-up between the group of patients with RDW values lower than 13.1% (25th percentile) and the group with RDW values higher than 14.1% (75th percentile), (4.3% vs. 17.1%, p < 0.0001). After adjusting for the covariates, RDW remained significantly associated with mortality in the whole cohort (HR-1.23 [95% CI (1.13-1.35), p < 0.0001]) and in the subgroups stratified by gender, age (over and under 75 years), presence of anemia, diabetes, heart failure and chronic kidney disease. CONCLUSION: Higher RDW values correspond to higher comorbidity burdens and higher mortality. RDW is an independent predictor of mortality in patients with stable coronary artery disease.
Subject(s)
Coronary Artery Disease/blood , Coronary Artery Disease/diagnosis , Erythrocyte Indices/physiology , Aged , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Prognosis , Retrospective StudiesABSTRACT
Thoracic aortic calcium deposits are frequently detected on tomography of the chest, and in other imaging modalities. Numerous studies indicated the correlation of hemodynamic parameters such as wall shear stress in relation to distribution aortic calcifications. This publication discusses similarities and differences of two distinct pathomechanisms of arterial calcifications: intimal associated with atherosclerosis and medial knows as Mönckeberg's arteriosclerosis. This review also analyzes the frequent coexistence of aortic calcification and coronary artery disease in terms of risk of cardiovascular events.
ABSTRACT
BACKGROUND: Diabetes (DM) deteriorates the prognosis in patients with coronary heart disease. However, the prognostic value of different glucose abnormalities (GA) other than DM in subjects with acute myocardial infarction (AMI) treated invasively remains unclear. AIMS: To assess the incidence and impact of GA on clinical outcomes in AMI patients treated with percutaneous coronary intervention (PCI). METHODS: A single-center, prospective registry encompassed 2733 consecutive AMI subjects treated with PCI. In all in-hospital survivors (n = 2527, 92.5%) without the history of DM diagnosed before or during index hospitalization standard oral glucose tolerance test (OGTT) was performed during stable condition before hospital discharge and interpreted according to WHO criteria. The mean follow-up period was 37.5 months. RESULTS: The incidence of GA was as follows: impaired fasting glycaemia - IFG (n = 376, 15%); impaired glucose tolerance - IGT (n = 560, 22%); DM (n = 425, 17%); new onset DM (n = 384, 15%); and normal glucose tolerance - NGT (n = 782, 31%). During the long-term follow-up, death rate events for previously known DM, new onset DM and IGT were significantly more frequent than those for IFG and NGT (12.3; 9.6 and 9.4 vs. 5.6 and 6.4%, respectively, P < 0.05). The strongest and common independent predictors of death in GA patients were glomerular filtration rate < 60 ml/min/1,73 m^2 (HR 2.0 and 2.8) and left ventricle ejection fraction < 35% (HR 2.5 and 1.8, all P < 0.05) respectively. CONCLUSIONS: Glucose abnormalities are very common in AMI patients. DM, new onset DM and IGT increase remote mortality. Impaired glucose tolerance bears similar long-term prognosis as diabetes.
Subject(s)
Blood Glucose/metabolism , Glucose Metabolism Disorders/blood , Myocardial Infarction/therapy , Percutaneous Coronary Intervention , Aged , Biomarkers/blood , Chi-Square Distribution , Female , Glomerular Filtration Rate , Glucose Metabolism Disorders/diagnosis , Glucose Metabolism Disorders/mortality , Glucose Tolerance Test , Humans , Incidence , Kaplan-Meier Estimate , Kidney/physiopathology , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/blood , Myocardial Infarction/diagnosis , Myocardial Infarction/mortality , Myocardial Infarction/physiopathology , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/mortality , Poland/epidemiology , Predictive Value of Tests , Proportional Hazards Models , Prospective Studies , Registries , Time Factors , Treatment Outcome , Ventricular Function, LeftABSTRACT
A 69-year-old woman was referred for cavotricuspid isthmus ablation due to typical isthmus-dependent right atrial flutter. During ablation, intracardiac activation sequence in coronary sinus (CS) changed without altering the cycle length or the P-wave morphology. This suggests that interatrial connection via CS was blocked and left atrium (LA) was activated from Bachmann's bundle or/and connections between fossa ovalis and LA.
Subject(s)
Atrial Flutter/physiopathology , Atrial Flutter/surgery , Catheter Ablation , Coronary Sinus/physiology , Aged , Atrial Flutter/diagnosis , Coronary Sinus/diagnostic imaging , Electrocardiography , Female , Fluoroscopy , Heart Atria/physiopathology , Heart Atria/surgery , Heart Septum/physiopathology , Heart Septum/surgery , HumansABSTRACT
Situs inversus with dextrocardia is a rare condition. Yet, the incidence of atheroclerosis and myocardial infarction in patients with dextrocardia is similar to that in general population. The diagnosis of acute myocardial infarction is somewhat tricky and difficult if the dextrocardia is not recognized. We present the electrocardiogram, coronary angiograms, and chest radiogram of a patient with incidentally found situs inversus with dextrocardia.